Published online before print January 5, 2006, doi: 10.1161/01.RES.0000202706.70992.95
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on September 12, 2005
Revised on December 15, 2005
Accepted on December 20, 2005
Acute Antiinflammatory Properties of Statins Involve Peroxisome Proliferator-Activated Receptor-
via Inhibition of the Protein Kinase C Signaling Pathway
Réjane Paumelle ;
From the Institut Pasteur de Lille (R.P., C.B., O. Briand, O. Barbier, C.D., F.P., J.-C.F., C.G., B.S.), Département d’Athérosclérose; INSERM, U545 (R.P., C.B., O. Briand, O. Barbier, C.D., F.P., J.-C.F., C.G., B.S.); Université de Lille 2 (R.P., C.B., O. Briand, O. Barbier, C.D., F.P., J.-C.F., C.G., B.S.); and INSERM, U547 (G.W., D.D.), Institut Pasteur de Lille, Lille, France.
* To whom correspondence should be addressed. E-mail: Bart.Staels{at}pasteur-lille.fr.
Statins are inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase used in the prevention of cardiovascular disease (CVD). In addition to their cholesterol-lowering activities, statins exert pleiotropic antiinflammatory effects, which might contribute to their beneficial effects not only on CVD but also on lipid-unrelated immune and inflammatory diseases, such as rheumatoid arthritis, asthma, stroke, and transplant rejection. However, the molecular mechanisms involved in these antiinflammatory properties of statins are unresolved. Here we show that the peroxisome proliferator-activated receptor (PPAR) 
mediates antiinflammatory effects of simvastatin in vivo in models of acute inflammation. The inhibitory effects of statins on lipopolysaccharide-induced inflammatory response genes were abolished in PPAR-deficient macrophages and neutrophils. Moreover, simvastatin inhibited PPAR phosphorylation by lipopolysaccharide-activated protein kinase C (PKC) . A constitutive active form of PKC inhibited nuclear factor 
B transrepression by PPAR whereas simvastatin enhanced transrepression activity of wild-type PPAR, but not of PPAR mutated in its PKC phosphorylation sites. These data indicate that the acute antiinflammatory effect of simvastatin occurs via PPAR by a mechanism involving inhibition of PKC inactivation of PPAR transrepression activity.
Key words: inflammation • macrophages • neutrophils • nuclear receptors • statins • PKC
Related Article:
- Novel Faces to Old Friends: A Central Role of Inducible NO Synthase for Progenitor Cell Recruitment and a New Antiinflammatory Mechanisms of Statins
- Ralf P. Brandes
Circ. Res. 2006 98: 303-305.[Full Text] [PDF]
This article has been cited by other articles:
 |
|
 |
|
  X. R. Chen, V. C. Besson, T. Beziaud, M. Plotkine, and C. Marchand-Leroux Combination Therapy with Fenofibrate, a Peroxisome Proliferator-Activated Receptor {alpha} Agonist, and Simvastatin, a 3-Hydroxy-3-methylglutaryl-Coenzyme A Reductase Inhibitor, on Experimental Traumatic Brain Injury J. Pharmacol. Exp. Ther., September 1, 2008; 326(3): 966 - 974. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Madsen, R. K. Petersen, K. R. Steffensen, L. M. Pedersen, P. Hallenborg, T. Ma, L. Froyland, S. O. Doskeland, J.-A. Gustafsson, and K. Kristiansen Activation of Liver X Receptors Prevents Statin-induced Death of 3T3-L1 Preadipocytes J. Biol. Chem., August 15, 2008; 283(33): 22723 - 22736. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. G. Mikael and R. Rozen Homocysteine modulates the effect of simvastatin on expression of ApoA-I and NF-{kappa}B/iNOS Cardiovasc Res, July 1, 2008; (2008) cvn157v2. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. C. Bucelli, E. A. Gonsiorek, W.-Y. Kim, D. Bruun, R. A. Rabin, D. Higgins, and P. J. Lein Statins Decrease Expression of the Proinflammatory Neuropeptides Calcitonin Gene-Related Peptide and Substance P in Sensory Neurons J. Pharmacol. Exp. Ther., March 1, 2008; 324(3): 1172 - 1180. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Desjardins, B. Sekkali, W. Verreth, M. Pelat, D. De Keyzer, A. Mertens, G. Smith, M.-C. Herregods, P. Holvoet, and J.-L. Balligand Rosuvastatin increases vascular endothelial PPAR{gamma} expression and corrects blood pressure variability in obese dyslipidaemic mice Eur. Heart J., January 1, 2008; 29(1): 128 - 137. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Paumelle and B. Staels Peroxisome Proliferator-Activated Receptors Mediate Pleiotropic Actions of Statins Circ. Res., May 25, 2007; 100(10): 1394 - 1395. [Full Text] [PDF]
|
|
|
|
|
|
M. Yano, T. Matsumura, T. Senokuchi, N. Ishii, Y. Murata, K. Taketa, H. Motoshima, T. Taguchi, K. Sonoda, D. Kukidome, et al. Statins Activate Peroxisome Proliferator-Activated Receptor {gamma} Through Extracellular Signal-Regulated Kinase 1/2 and p38 Mitogen-Activated Protein Kinase-Dependent Cyclooxygenase-2 Expression in Macrophages Circ. Res., May 25, 2007; 100(10): 1442 - 1451. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. S. Elton and M. M. Martin Angiotensin II Type 1 Receptor Gene Regulation: Transcriptional and Posttranscriptional Mechanisms Hypertension, May 1, 2007; 49(5): 953 - 961. [Full Text] [PDF]
|
|
|
|
|
|
M. A. Yakubu, R. H. Nsaif, and A. O. Oyekan Peroxisome Proliferator-Activated Receptor {alpha} Activation-Mediated Regulation of Endothelin-1 Production via Nitric Oxide and Protein Kinase C Signaling Pathways in Piglet Cerebral Microvascular Endothelial Cell Culture J. Pharmacol. Exp. Ther., February 1, 2007; 320(2): 774 - 781. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Yessoufou, A. Hichami, P. Besnard, K. Moutairou, and N. A. Khan Peroxisome Proliferator-Activated Receptor {alpha} Deficiency Increases the Risk of Maternal Abortion and Neonatal Mortality in Murine Pregnancy with or without Diabetes Mellitus: Modulation of T Cell Differentiation Endocrinology, September 1, 2006; 147(9): 4410 - 4418. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. P. Brandes Novel Faces to Old Friends: A Central Role of Inducible NO Synthase for Progenitor Cell Recruitment and a New Antiinflammatory Mechanisms of Statins Circ. Res., February 17, 2006; 98(3): 303 - 305. [Full Text] [PDF]
|
|